Moreover, as 53BP1 is able to regulate the tumor cell sensitivity to PARP inhibitor in BRCA tumors, our structure analysis on the complex of TIRR and 53BP1 provides the opportunities for developing chemical probes to regulate the activity of 53BP1, which may facilitate clinical cancer treatment in future. The gene discussed is NUDT16L1; the disease is cancer.